Home » Stocks » Adaptimmune Therapeutics

Adaptimmune Therapeutics PLC (ADAP)

Stock Price: $5.39 USD -0.21 (-3.75%)
Updated Oct 20, 2020 4:00 PM EDT - Market closed
After-hours: $5.40 +0.01 (0.19%) Oct 20, 5:54 PM

Stock Price Chart

Key Info

Market Cap 833.62M
Revenue (ttm) 2.23M
Net Income (ttm) -126.71M
Shares Out 154.66M
EPS (ttm) -1.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 20, 2020
Last Price $5.39
Previous Close $5.60
Change ($) -0.21
Change (%) -3.75%
Day's Open 5.62
Day's Range 5.19 - 5.73
Day's Volume 2,054,617
52-Week Range 0.71 - 13.40

More Stats

Market Cap 833.62M
Enterprise Value 433.62M
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 154.66M
Float 136.00M
EPS (basic) -1.14
EPS (diluted) -1.08
FCF / Share -0.37
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 5.32M
Short Ratio 7.28
Short % of Float 3.91%
Beta 2.12
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 374.16
PB Ratio 3.00
Revenue 2.23M
Operating Income -130.49M
Net Income -126.71M
Free Cash Flow -51.04M
Net Cash 400.01M
Net Cash / Share 2.59
Gross Margin -4,325.81%
Operating Margin -5,856.96%
Profit Margin -5,687.30%
FCF Margin -2,291.02%
ROA -21.70%
ROE -42.62%
ROIC -61.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 4
Overweight 0
Hold 4
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

(135.06% upside)
Current: $5.39
Target: 12.67
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-98.11%57.28%166.47%43.84%1096.48%-
Gross Profit1.1259.5137.8314.209.870.83
Operating Income-140-82.37-80.66-72.80-24.64-11.52
Net Income-137-95.51-70.14-71.58-22.06-11.60
Shares Outstanding630584528425215148
Earnings Per Share-1.32-0.96-0.78-1.02-1.02-0.48
Operating Cash Flow-113-104-54.32-48.17-29.6736.84
Capital Expenditures-1.59-3.91-24.09-11.51-4.96-1.37
Free Cash Flow-114-108-78.41-59.67-34.6235.47
Cash & Equivalents94.04209213185284-
Total Debt25.46-----
Net Cash / Debt68.58209213185284-
Book Value124247203166259-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Adaptimmune Therapeutics PLC
Country United Kingdom
Employees 399
CEO Adrian Rawcliffe

Stock Information

Ticker Symbol ADAP
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ADAP
IPO Date May 6, 2015


Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma. The company has a strategic collaboration and license agreement with GSK to research, develop, and commercialize NY-ESO T-cell therapy; and collaboration agreement with Noile-Immune Biotech Inc. to develop SPEAR T-cells in combination with Noile-Immune's PRIME technology. It also has a co-development and co-commercialization agreement with Universal Cells, Inc to bring new stem-cell derived allogeneic T-Cell therapies to people with cancer. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.